Barry M. Rosenfeld is a seasoned General Counsel and senior executive with a track record of delivering strategic solutions in highly regulated, technology-driven industries such as biopharmaceuticals, generics, and over-the-counter medicines. With decades of expertise spanning mergers and acquisitions, financing, product development, intellectual property, corporate governance, and litigation, Barry has successfully guided both early-stage and multinational companies through complex challenges and transformative growth. His career reflects a deep commitment to enabling business objectives while balancing risk and compliance in diverse global markets.

In his role as Senior Vice President, General Counsel, and Corporate Secretary at Oyster Point Pharma, Barry played a pivotal role in the company’s evolution from an early-stage pharmaceutical enterprise to a full-service business. He steered the legal and corporate governance functions during key milestones, including the launch of two ophthalmic products and the company’s $329 million acquisition by Viatris Inc. His leadership extended to the involvement in a $125 million financing deal and out-licensing a product to a Chinese pharmaceutical firm. Barry’s expertise in product launches was instrumental, as he guided legal aspects of marketing campaigns, patient support services, and reimbursement frameworks.

Before Oyster Point, Barry founded B. Rosenfeld LLC, where he served as an outside General Counsel, advising clients on contracts, compliance, and corporate governance. He crafted strategies for biotechnology companies preparing for regulatory approvals and facilitated agreements supporting COVID-19 vaccine development.

During his tenure at Novartis, Barry rose through increasingly senior legal roles, ultimately serving as Vice President, General Counsel, and Corporate Secretary for Novartis Finance Corporation. He managed legal complexities across securities law, investor relations, corporate governance, and litigation for the U.S. holding companies of this Swiss multinational. Barry’s leadership included assisting with governance innovations for entities representing over $17 billion in revenues. He also demonstrated foresight as Novartis’ first privacy lawyer, implementing European Union privacy regulations. His experience spans advising on global licensing deals with industry leaders, supporting marketing strategies for iconic consumer health brands, and championing legal approaches to biosimilars and generics.

Barry’s legal acumen extends to his tenure as Interim General Counsel for both Sandoz Inc. and Novartis Nutrition Corporation, where he led legal teams through significant industry transitions, including acquisitions and integration processes. He also contributed as Site Counsel at Ciba-Geigy Corporation, managing the legal aspects of the $300 million closure and remediation of a chemical manufacturing facility.

A former Litigation Associate at Kaye Scholer and Law Clerk to U.S. District Court Judges Richard Owen and Inzer B. Wyatt, Barry began his career with a foundation of excellence. He holds a Juris Doctor degree from New York University School of Law, where he earned the American Jurisprudence Prize in Constitutional Law, and a Bachelor of Arts with High Honors from the University of Michigan.

Barry M. Rosenfeld’s leadership has consistently delivered innovative legal solutions that empower organizations to thrive in complex regulatory environments, making him a trusted advisor and integral asset in the biopharmaceutical and healthcare sectors.

• Character: Barry M. Rosenfeld exemplifies integrity, resilience, and a commitment to excellence in delivering legal solutions in high-pressure, regulated environments.
• Knowledge: He possesses deep expertise across corporate law, intellectual property, compliance, and governance in the biopharmaceutical and healthcare sectors.
• Strategic: Barry is a forward-thinking leader who aligns legal strategies with business objectives to drive growth, manage risk, and secure competitive advantages.
• Communication: He excels in fostering collaboration, conveying complex legal concepts clearly, and building consensus among diverse stakeholders globally.